Abstract
A phase II study of vindesine in 41 evaluable patients demonstrated the drug to be active in heavily pretreated patients ith breast cancer, non-Hodgkin's lymphoma, and other tumors. There were two partial responses in 11 patients with breast ancer (18%) and five partial responses and one complete response in 11 patients with non-Hodgkin's lymphoma (40%). Other esponses were seen in small cell carcinoma of the lung, ovarian carcinoma, and Hodgkin's disease. Prior vinca exposure did nt adversely affect the response rate. Neutropenia was dose-limiting. Neurotoxic effects occurred in 10% of the patients. high incidence of local tissue reactions at the injection site (27%) could be reduced by a careful administration technique Vindesine should be studied further in combination with other agents.
Original language | English (US) |
---|---|
Pages (from-to) | 1001-1003 |
Number of pages | 3 |
Journal | Cancer Treatment Reports |
Volume | 64 |
Issue number | 8-9 |
State | Published - Dec 1 1980 |
ASJC Scopus subject areas
- Oncology
- Cancer Research